Anti-tumor immunity in head and neck cancer: Understanding the evidence, how tumors escape and immunotherapeutic approaches

Cancers

Volumn 7, Issue 4, 2015, Pages 2397-2414

  Allen, Clint T ^a,b   Clavijo, Paul E ^a   Van Waes, Carter ^a   Chen, Zhong ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Antigenicity; Checkpoint inhibitors; Immunogenicity; Immunosuppression; Immunotherapy; Innate immunity; Syngeneic mouse models; Tumor antigen; Vaccines

Indexed keywords

CETUXIMAB; TADALAFIL; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANTIGENICITY; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84949778471     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040900     Document Type: Review

References (110)

1. Chen, Z.; Rosten, S.I.; Lord, E.M.; Gaspari, A.A. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms. Reg. Immunol. 1993, 5, 285–292. [PubMed]
2. Yeh, K.Y.; Chen, Z.; Nasir, A.; Ohsuga, Y.; Takashima, A.; Lord, E.M.; Gaspari, A.A. Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth. J. Investig. Dermatol. 1997, 109, 728–733. [CrossRef] [PubMed]
3. Chen, Z.; Smith, C.W.; Kiel, D.; vanWaes, C. Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction. Clin. Exp. Metastasis 1997, 15, 527–537. [CrossRef] [PubMed]
4. Dong, G.; Chen, Z.; Kato, T.; van Waes, C. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 1999, 59, 3495–3504. [PubMed]
5. Smith, C.W.; Chen, Z.; Dong, G.; Loukinova, E.; Pegram, M.Y.; Nicholas-Figueroa, L.; van Waes, C. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1a, IL-6, GM-CSF, and KC. Clin. Exp. Metastasis 1998, 16, 655–664. [CrossRef] [PubMed]
6. Dong, G.; Lee, T.L.; Yeh, N.T.; Geoghegan, J.; van Waes, C.; Chen, Z. Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene 2004, 23, 6199–6208. [CrossRef] [PubMed]
7. Loukinova, E.; Dong, G.; Enamorado-Ayalya, I.; Thomas, G.R.; Chen, Z.; Schreiber, H.; van Waes, C. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000, 19, 3477–3486. [CrossRef] [PubMed]
8. Loukinova, E.; Chen, Z.; vanWaes, C.; Dong, G. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1a, EGF and TGF-b1 through NF-kB dependent and independent mechanisms. Int. J. Cancer 2001, 94, 637–644. [CrossRef] [PubMed]
9. Dong, G.; Loukinova, E.; Chen, Z.; Gangi, L.; Chanturita, T.I.; Liu, E.T.; vanWaes, C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kB signal pathway. Cancer Res. 2001, 61, 4797–4808. [PubMed]
10. Loercher, A.; Lee, T.L.; Ricker, J.L.; Howard, A.; Geoghegen, J.; Chen, Z.; Sunwoo, J.B.; Sitcheran, R.; Chuang, E.Y.; Mitchell, J.B., et al. Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004, 64, 6511–6523. [CrossRef] [PubMed]
11. Gill, R.C.Z.; Nejad-Sattarri, M.; Loos, B.; Park, C.; Yeh, N.T.; Kass, E.; van Waes, C. Squamous cell carcinoma expressing proinflammatory cytokines produce T helper 1 unresponsivenenss and increased myeloid and T helper 2 type cytokine responses. In Proceedings of the 6th ResearchWorkshop on Biology, Prevention and Therapy of Head and Neck Cancer, McLean, VA, USA, 9–13 October 2002.
12. Thomas, G.R.; Chen, Z.; Oechsli, M.N.; Hendler, F.J.; van Waes, C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int. J. Cancer 1999, 82, 377–384. [CrossRef]
13. Thomas, G.R.; Chen, Z.; Enamorado, I.; Bancroft, C.; vanWaes, C. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-. Int. J. Cancer 2000, 86, 368–374. [CrossRef]
14. Thomas, G.R.; Chen, Z.; Leukinova, E.; van Waes, C.; Wen, J. Cytokines IL-1a, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: Restoration by interferon gamma. Cancer Immunol. Immunother. 2004, 53, 33–40. [CrossRef] [PubMed]
15. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517, 576–582.
16. King, K.E.; Ponnamperuma, R.M.; Allen, C.; Lu, H.; Duggal, P.; Chen, Z.; van Waes, C.; Weinberg, W.C. The p53 homologue DNp63a interacts with the nuclear factor-kB pathway to modulate epithelial cell growth. Cancer Res. 2008, 68, 5122–5131. [CrossRef] [PubMed]
17. Lu, H.; Yang, X.; Duggal, P.; Allen, C.T.; Yan, B.; Cohen, J.; Nottingham, L.; Romano, R.A.; Sinha, S.; King, K.E., et al. TNF-k promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res. 2011, 71, 6867–6877. [CrossRef] [PubMed]
18. Yang, X.; Lu, H.; Yan, B.; Romano, R.A.; Bian, Y.; Friedman, J.; Duggal, P.; Allen, C.; Chuang, R.; Ehsanian, R., et al. DNp63 versatilely regulates a Broad NF-kB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011, 71, 3688–3700. [CrossRef] [PubMed]
19. Du, J.; Romano, R.A.; Si, H.; Mattox, A.; Bian, Y.; Yang, X.; Sinha, S.; van Waes, C.; Chen, Z. Epidermal overexpression of transgenic DNp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF-kB activation. J. Pathol. 2014, 232, 356–368. [CrossRef] [PubMed]
20. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410, 1107–1111. [CrossRef] [PubMed]
21. Diamond, M.S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G.P.; Archambault, J.M.; Lee, H.; Arthur, C.D.; White, J.M.; Kalinke, U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208, 1989–2003. [CrossRef] [PubMed]
22. + dendritic cells. J. Exp. Med. 2011, 208, 2005–2016. [CrossRef] [PubMed]
23. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
24. Blankenstein, T.; Coulie, P.G.; Gilboa, E.; Jaffee, E.M. The determinants of tumour immunogenicity. Nat. Rev. Cancer 2012, 12, 307–313. [CrossRef] [PubMed]
25. Allen, C.T.; Judd, N.P.; Bui, J.D.; Uppaluri, R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 2012, 122, 144–157. [CrossRef] [PubMed]
26. Yadav, M.; Jhunjhunwala, S.; Phung, Q.T.; Lupardus, P.; Tanguay, J.; Bumbaca, S.; Franci, C.; Cheung, T.K.; Fritsche, J.; Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515, 572–576. [CrossRef] [PubMed]
27. Gubin, M.M.; Zhang, X.; Schuster, H.; Caron, E.; Ward, J.P.; Noguchi, T.; Ivanova, Y.; Hundal, J.; Arthur, C.D.; Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515, 577–581. [CrossRef] [PubMed]
28. Duan, F.; Duitama, J.; Al Seesi, S.; Ayres, C.M.; Corcelli, S.A.; Pawashe, A.P.; Blanchard, T.; McMahon, D.; Sidney, J.; Sette, A., et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 2014, 211, 2231–2248. [CrossRef] [PubMed]
29. Champiat, S.; Ferte, C.; Lebel-Binay, S.; Eggermont, A.; Soria, J.C. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014, 3, e27817. [CrossRef] [PubMed]
30. Khong, H.T.; Restifo, N.P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 2002, 3, 999–1005. [CrossRef] [PubMed]
31. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991–998. [CrossRef] [PubMed]
32. Snyder, A.; Makarov, V.; Merghoub, T.; Yuan, J.; Zaretsky, J.M.; Desrichard, A.; Walsh, L.A.; Postow, M.A.; Wong, P.; Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371, 2189–2199. [CrossRef] [PubMed]
33. Coley, W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 1910, 3, 1–48. [PubMed]
34. Wolf, G.T.; Chepeha, D.B.; Bellile, E.; Nguyen, A.; Thomas, D.; McHugh, J. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study. Oral. Oncol. 2015, 51, 90–95. [CrossRef] [PubMed]
35. Keck, M.K.; Zuo, Z.; Khattri, A.; Stricker, T.P.; Brown, C.D.; Imanguli, M.; Rieke, D.; Endhardt, K.; Fang, P.; Bragelmann, J., et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin. Cancer Res. 2015, 21, 870–881. [CrossRef] [PubMed]
36. Balermpas, P.; Michel, Y.; Wagenblast, J.; Seitz, O.; Weiss, C.; Rodel, F.; Rodel, C.; Fokas, E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 2014, 110, 501–509. [CrossRef] [PubMed]
37. Nasman, A.; Romanitan, M.; Nordfors, C.; Grun, N.; Johansson, H.; Hammarstedt, L.; Marklund, L.; Munck-Wikland, E.; Dalianis, T.; Ramqvist, T. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS ONE 2012, 7, e38711. [CrossRef] [PubMed]
38. Balermpas, P.; Rodel, F.; Rodel, C.; Krause, M.; Linge, A.; Lohaus, F.; Baumann, M.; Tinhofer, I.; Budach, V.; Gkika, E., et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int. J. Cancer 2015. [CrossRef] [PubMed]
39. Klein, G.; Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: Contrasting consequences of host versus tumor evolution. Proc. Natl. Acad. Sci. USA 1977, 74, 2121–2125. [CrossRef] [PubMed]
40. Mroz, E.A.; Tward, A.D.; Hammon, R.J.; Ren, Y.; Rocco, J.W. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: Analysis of data from the Cancer Genome Atlas. PLoS Med. 2015, 12, e1001786. [CrossRef] [PubMed]
41. Willimsky, G.; Czeh, M.; Loddenkemper, C.; Gellermann, J.; Schmidt, K.; Wust, P.; Stein, H.; Blankenstein, T. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 2008, 205, 1687–1700. [CrossRef] [PubMed]
42. Janicki, C.N.; Jenkinson, S.R.; Williams, N.A.; Morgan, D.J. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res. 2008, 68, 2993–3000. [CrossRef] [PubMed]
43. Pradeu, T.; Carosella, E.D. On the definition of a criterion of immunogenicity. Proc. Natl. Acad. Sci. USA 2006, 103, 17858–17861. [CrossRef] [PubMed]
44. Krysko, D.V.; Garg, A.D.; Kaczmarek, A.; Krysko, O.; Agostinis, P.; Vandenabeele, P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12, 860–875. [CrossRef] [PubMed]
45. Barber, G.N. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014, 35, 88–93. [CrossRef] [PubMed]
46. Liu, Y.; Zeng, G. Cancer and innate immune system interactions: Translational potentials for cancer immunotherapy. J. Immunother. 2012, 35, 299–308. [CrossRef] [PubMed]
47. Farnebo, L.; Shahangian, A.; Lee, Y.; Shin, J.H.; Scheeren, F.A.; Sunwoo, J.B. Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget 2015, 6, 9897–9907. [CrossRef] [PubMed]
48. Ferris, L.R.; Whiteside, T.L.; Ferrone, S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin. Cancer Res. 2006, 12, 3890–3895. [CrossRef] [PubMed]
49. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6, 715–727. [CrossRef] [PubMed]
50. Ariffin, A.B.; Forde, P.F.; Jahangeer, S.; Soden, D.M.; Hinchion, J. Releasing pressure in tumors: What do we know so far and where do we go from here? A review. Cancer Res. 2014, 74, 2655–2662. [CrossRef] [PubMed]
51. Farsaci, B.; Donahue, R.N.; Coplin, M.A.; Grenga, I.; Lepone, L.M.; Molinolo, A.A.; Hodge, J.W. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol. Res. 2014, 2, 1090–1102. [CrossRef] [PubMed]
52. Hamzah, J.; Jugold, M.; Kiessling, F.; Rigby, P.; Manzur, M.; Marti, H.H.; Rabie, T.; Kaden, S.; Grone, H.J.; Hammerling, G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453, 410–414. [CrossRef] [PubMed]
53. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441–1454. [CrossRef] [PubMed]
54. Kwilas, A.R.; Donahue, R.N.; Tsang, K.Y.; Hodge, J.W. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2015, 2. [CrossRef]
55. Bedi, A.; Chang, X.; Noonan, K.; Pham, V.; Bedi, R.; Fertig, E.J.; Considine, M.; Califano, J.A.; Borrello, I.; Chung, C.H., et al. Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol. Cancer Ther. 2012, 11, 2429–2439. [CrossRef] [PubMed]
56. Dong, G.; Chen, Z.; Li, Z.Y.; Yeh, N.T.; Bancroft, C.C.; van Waes, C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001, 61, 5911–5918. [PubMed]
57. Gabrilovich, I.D.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162–174. [CrossRef] [PubMed]
58. Highfill, S.L.; Cui, Y.; Giles, A.J.; Smith, J.P.; Zhang, H.; Morse, E.; Kaplan, R.N.; Mackall, C.L. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Trans. Med. 2014, 6. [CrossRef] [PubMed]
59. Katoh, H.; Wang, D.; Daikoku, T.; Sun, H.; Dey, S.K.; Dubois, R.N. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013, 24, 631–644. [CrossRef] [PubMed]
60. Lesokhin, A.M.; Hohl, T.M.; Kitano, S.; Cortez, C.; Hirschhorn-Cymerman, D.; Avogadri, F.; Rizzuto, G.A.; Lazarus, J.J.; Pamer, E.G.; Houghton, A.N., et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012, 72, 876–886. [CrossRef] [PubMed]
61. Vasquez-Dunddel, D.; Pan, F.; Zeng, Q.; Gorbounov, M.; Albesiano, E.; Fu, J.; Blosser, R.L.; Tam, A.J.; Bruno, T.; Zhang, H., et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Investig. 2013, 123, 1580–1589. [CrossRef] [PubMed]
62. Bronte, V.; Apolloni, E.; Cabrelle, A.; Ronca, R.; Serafini, P.; Zamboni, P.; Restifo, N.P.; Zanovello, P. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 2000, 96, 3838–3846. [PubMed]
63. Srivastava, M.K.; Zhu, L.; Harris-White, M.; Kar, U.K.; Huang, M.; Johnson, M.F.; Lee, J.M.; Elashoff, D.; Strieter, R.; Dubinett, S., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 2012, 7, e40677. [CrossRef] [PubMed]
64. Stromnes, I.M.; Brockenbrough, J.S.; Izeradjene, K.; Carlson, M.A.; Cuevas, C.; Simmons, R.M.; Greenberg, P.D.; Hingorani, S.R. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014, 63, 1769–1781. [CrossRef] [PubMed]
65. Keane, M.P.; Belperio, J.A.; Xue, Y.Y.; Burdick, M.D.; Strieter, R.M. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 2004, 172, 2853–2360. [CrossRef] [PubMed]
66. Zhu, Y.; Knolhoff, B.L.; Meyer, M.A.; Nywening, T.M.; West, B.L.; Luo, J.; Wang-Gillam, A.; Goedegebuure, S.P.; Linehan, D.C.; DeNardo, D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74, 5057–5069. [CrossRef] [PubMed]
67. Califano, J.A.; Khan, Z.; Noonan, K.A.; Rudraraju, L.; Zhang, Z.; Wang, H.; Goodman, S.; Gourin, C.G.; Ha, P.K.; Fakhry, C., et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2015, 21, 30–38. [CrossRef] [PubMed]
68. Young, M.R.; Wright, M.A.; Lozano, Y.; Prechel, M.M.; Benefield, J.; Leonetti, J.P.; Collins, S.L.; Petruzzelli, G.J. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int. J. Cancer 1997, 74, 69–74. [CrossRef]
69. Yu, J.; Wang, Y.; Yan, F.; Zhang, P.; Li, H.; Zhao, H.; Yan, C.; Yan, F.; Ren, X. Noncanonical NF-kB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 2014, 193, 2574–2586. [CrossRef] [PubMed]
70. Noy, R.; Pollard, J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41, 49–61. [CrossRef] [PubMed]
71. O'Sullivan, T.; Saddawi-Konefka, R.; Vermi, W.; Koebel, C.M.; Arthur, C.; White, J.M.; Uppaluri, R.; Andrews, D.M.; Ngiow, S.F.; Teng, M.W., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 2012, 209, 1869–1882. [CrossRef] [PubMed]
72. Costa, N.L.; Valadares, M.C.; Souza, P.P.; Mendonca, E.F.; Oliveira, J.C.; Silva, T.A.; Batista, A.C. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral. Oncol. 2013, 49, 216–223. [CrossRef] [PubMed]
73. Knutson, L.K.; Disis, M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005, 54, 721–728. [CrossRef] [PubMed]
74. Jie, H.B.; Gildener-Leapman, N.; Li, J.; Srivastava, R.M.; Gibson, S.P.; Whiteside, T.L.; Ferris, R.L. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br. J. Cancer 2013, 109, 2629–2635. [CrossRef] [PubMed]
75. Strauss, L.; Bergmann, C.; Szczepanski, M.; Gooding, W.; Johnson, J.T.; Whiteside, T.L. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007, 13, 4345–4354. [CrossRef] [PubMed]
76. Lau, K.M.; Cheng, S.H.; Lo, K.W.; Lee, S.A.; Woo, J.K.; van Hasselt, C.A.; Lee, S.P.; Rickinson, A.B.; Ng, M.H. Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients. Br. J. Cancer 2007, 96, 617–622. [CrossRef] [PubMed]
77. Schaefer, C.; Kim, G.G.; Albers, A.; Hoermann, K.; Myers, E.N.; Whiteside, T.L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 2005, 92, 913–920. [CrossRef] [PubMed]
78. De Costa, A.M.; Schuyler, C.A.; Walker, D.D.; Young, M.R. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2012, 61, 927–939. [CrossRef] [PubMed]
79. Willimsky, G.; Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437, 141–146. [CrossRef] [PubMed]
80. Zou, W.; Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8, 467–477. [CrossRef] [PubMed]
81. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002, 8, 793–800. [CrossRef] [PubMed]
82. Topalian, L.S.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015, 27, 450–461. [CrossRef] [PubMed]
83. Spranger, S.; Spaapen, R.M.; Zha, Y.; Williams, J.; Meng, Y.; Ha, T.T.; Gajewski, T.F. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Trans. Med. 2013, 5. [CrossRef] [PubMed]
84. Taube, J.M.; Anders, R.A.; Young, G.D.; Xu, H.; Sharma, R.; McMiller, T.L.; Chen, S.; Klein, A.P.; Pardoll, D.M.; Topalian, S.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Trans. Med. 2012, 4. [CrossRef] [PubMed]
85. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [CrossRef] [PubMed]
86. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [CrossRef] [PubMed]
87. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [CrossRef] [PubMed]
88. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crino, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 123–135. [CrossRef] [PubMed]
89. Barbee, M.S.; Ogunniyi, A.; Horvat, T.Z.; Dang, T.O. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Ann. Pharmacother. 2015, 49, 907–937. [CrossRef] [PubMed]
90. Weed, D.T.; Vella, J.L.; Reis, I.M.; De la Fuente, A.C.; Gomez, C.; Sargi, Z.; Nazarian, R.; Califano, J.; Borrello, I.; Serafini, P. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2015, 21, 39–48. [CrossRef] [PubMed]
91. Stadtmann, A.; Zarbock, A. CXCR2: From Bench to Bedside. Front. Immunol. 2012, 3, 263. [CrossRef] [PubMed]
92. Downey, C.M.; Aghaei, M.; Schwendener, R.A.; Jirik, F.R. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2131-cGAMP, induces M2 macrophage repolarization. PLoS ONE 2014, 9, e99988. [CrossRef] [PubMed]
93. Lizotte, P.H.; Baird, J.R.; Stevens, C.A.; Lauer, P.; Green, W.R.; Brockstedt, D.G.; Fiering, S.N. Attenuated reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. Oncoimmunology 2014, 3, e28926. [CrossRef] [PubMed]
94. Buhtoiarov, I.N.; Sondel, P.M.; Wigginton, J.M.; Buhtoiarova, T.N.; Yanke, E.M.; Mahvi, D.A.; Rakhmilevich, A.L. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 2011, 132, 226–239. [CrossRef] [PubMed]
95. Whelan, M.C.; Casey, G.; Larkin, J.O.; Guinn, B.A.; O'Sullivan, G.C.; Tangney, M. Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS ONE 2014, 9, e97602. [CrossRef] [PubMed]
96. Jacobs, J.F.; Punt, C.J.; Lesterhuis, W.J.; Sutmuller, R.P.; Brouwer, H.M.; Scharenborg, N.M.; Klasen, I.S.; Hilbrands, L.B.; Figdor, C.G.; de Vries, I.J., et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010, 16, 5067–5078. [CrossRef] [PubMed]
97. Schlom, J. Therapeutic cancer vaccines: Current status and moving forward. J. Natl. Cancer Inst. 2012, 104, 599–613. [CrossRef] [PubMed]
98. Voskens, C.J.; Sewell, D.; Hertzano, R.; DeSanto, J.; Rollins, S.; Lee, M.; Taylor, R.; Wolf, J.; Suntharalingam, M.; Gastman, B., et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 2012, 34, 1734–1746. [CrossRef] [PubMed]
99. Zandberg, D.P.; Rollins, S.; Goloubeva, O.; Morales, R.E.; Tan, M.; Taylor, R.; Wolf, J.S.; Schumaker, L.M.; Cullen, K.J.; Zimrin, A., et al. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol. Immunother. 2015, 64, 367–379. [CrossRef] [PubMed]
100. Schuler, P.J.; Harasymczuk, M.; Visus, C.; Deleo, A.; Trivedi, S.; Lei, Y.; Argiris, A.; Gooding, W.; Butterfield, L.H.; Whiteside, T.L., et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin. Cancer Res. 2014, 20, 2433–2444. [CrossRef] [PubMed]
101. Yoshitake, Y.; Fukuma, D.; Yuno, A.; Hirayama, M.; Nakayama, H.; Tanaka, T.; Nagata, M.; Takamune, Y.; Kawahara, K.; Nakagawa, Y., et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res. 2015, 21, 312–321. [CrossRef] [PubMed]
102. Rosenberg, A.S.; Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348, 62–68. [CrossRef] [PubMed]
103. Kalos, M.; June, C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39, 49–60. [CrossRef] [PubMed]
104. Ohtani, T.; Yamada, Y.; Furuhashi, A.; Ohmura, Y.; Nakamura, S.; Kato, H.; Yoshikawa, K.; Kazaoka, Y. Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers. Int. J. Oncol. 2014, 45, 2051–2207. [CrossRef] [PubMed]
105. Reeves, T.D.; Hill, E.G.; Armeson, K.E.; Gillespie, M.B. Cetuximab therapy for head and neck squamous cell carcinoma: A systematic review of the data. Otolaryngol. Head Neck Surg. 2011, 144, 676–684. [CrossRef] [PubMed]
106. Srivastava, R.M.; Lee, S.C.; Andrade Filho, P.A.; Lord, C.A.; Jie, H.B.; Davidson, H.C.; Lopez-Albaitero, A.; Gibson, S.P.; Gooding, W.E.; Ferrone, S., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 2013, 19, 1858–1872. [CrossRef] [PubMed]
107. Trivedi, S.; Jie, H.B.; Ferris, R.L. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin. Oncol. 2014, 41, 678–684. [CrossRef] [PubMed]
108. Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372, 2006–2017. [CrossRef] [PubMed]
109. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568–571. [CrossRef] [PubMed]
110. Seiwert, T.Y.; Burtness, B.; Weiss, J.; Gluck, I.; Eder, P.J.; Pai, S.; Dolled-Filhart, M.; Emancipator, K.; Pathiraja, K.; Gause, C., et al. A phase iB study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer, ASCO Annual Meeting Abstracts. J. Clin. Oncol. 2014, 32, 6011.